WELCOME
Gardy & Notis, LLP is a boutique law firm dedicated to representing investors in securities class actions, derivative actions, and merger and acquisition litigation, and representing consumers in consumer fraud cases.
Read More
NEWS
June 08, 2022
Gardy & Notis, LLP is co-lead counsel for stockholders suing certain current and former directors and other insiders of Renren, Inc. for transferring Renren's investment portfolio to an entity controlled by Renren's CEO at a severely undervalued price in June 2018.
May 27, 2022
Gardy & Notis, LLP is a court appointed lead counsel for stockholders suing certain current and former members of the board of directors of Cardinal Health, Inc. for breaching their fiduciary obligations in failing to monitor and report suspicious sales of prescription opioids as required by the Controlled Substances Act.
February 08, 2021
Gardy & Notis, LLP is lead counsel for investors suing certain current and former members of the board of directors of Cardinal Health, Inc. for breaching their fiduciary obligations in failing to monitor suspicious sales of controlled substance pharmaceuticals and report suspicious sales as required by the Controlled Substances Act.
February 07, 2021
Gardy & Notis, LLP is co-lead counsel for investors suing certain current and former directors and other insiders of Renren, Inc., aided and abetted by Duff & Phelps, for transferring Renren's investment portfolio to an entity controlled by Renren's CEO at a severely undervalued price.
April 22, 2020
Gardy & Notis, LLP is a court appointed lead counsel for stockholders suing McKesson Corporation's officers and directors for breach of their fiduciary obligations to the company by failing to provide oversight of McKesson's compliance with the Controlled Substances Act and related regulations.
October 11, 2019
Gardy & Notis, LLP is the court appointed lead counsel for investors who bought American Depositary Shares (ADS) and options of Shire plc between September 29, 2014 and October 14, 2014. Gardy & Notis, LLP pursued claims that AbbVie, Inc. and its Chief Executive Officer defrauded Shire plc investors by making false statements regarding AbbVie's planned merger with Shire.